Methods
Information of the patients' gender, age, weight, height, intervention (surgery and/or radiotherapy) and hormonal analytical data (FSH, LH, total testosterone, free testosterone, oestradiol and responses to GnRH test) were recorded. Tumors were divided according to size in microadenomas (<10mm) and macroadenomas (>10mm). Patients were first classified in 2 groups: normal PGS (normal) and hypogonadotropic hypogonadism (HH). Females in menopause with hypergonadotropic hypogonadism were classified as "normal", since this is the physiologic response and translates a functionally normal pituitary. The hormone levels and weight recorded were from the last evaluation before surgery and the first evaluation within 3 to 9 months after surgery for the operated patients. The recorded levels for the patients that did not undergo surgery were from the last known evaluation. The vast majority of patients were tested by our lab. Patients evaluated until 2006 had the determination of FSH, LH, oestradiol and total testosterone made by chemiluminescence on Abbott -Architect. After 2006 they were determined using electrochemiluminescence on Cobas e411. On both periods free testosterone was measured by radioimmunoassay. Used reference ranges were the ones provided by the respective laboratory at the given moment, for the patient's gender and age. In male patients HH was defined if: -Testosterone was low and: if both FSH and LH were low; if LH was low; if FSH and LH were within the normal reference range, since the gonadotropins were inappropriately normal (the normal response to low levels of testosterone would be to be elevated) [7, 14] -Testosterone was normal but the patient was under TRT: if both FSH and LH were low; if LH was low [15] In female patients HH was defined if: -In pre-menopause: oestradiol was low and both FSH and LH were low; if FSH and LH were inappropriately normal (as explained for males) -In post-menopause oestradiol is low by definition (hypergonadotropic hypogonadism). To be classified as HH both FSH and LH had to be 20% below the inferior limit of the reference range for that group (higher than pre-menopause females)
If patients were included in the HH group, response to synthetic Gonadotropin-Releasing-Hormone (GnRH) was analyzed. The GnRH test was done by administering 100 μg of synthetic GnRH and drawing blood for FSH and LH values at 0, 15, 30, 60, 90 and 120 minutes. A positive response to the GnRH was established if FSH raised 1.5 times the basal value or if LH raised 2 times the basal value, in females, 3 times the basal value, in males [16, 17] . If there was a response to the stimulation with GnRH, the cause of the HH was deficient hypothalamic hormone secretion and the pituitary remained functional. A nonresponse to GnRH stimulus translated a non-functioning pituitary, with or without hypothalamic damage. Of the 43 patients with HH before intervention (27 males and 16 females), only 30 (21 males and 9 females) had data from GnRH stimulation. Of the 32 patients with HH after surgery (20 males and 12 females) only 17 (9 males and 8 females) had data from GnRH stimulation.
The Androgen Deficiency in Aging Males (ADAM) questionnaire, validated to assess ED was applied to all living male patients. The questionnaire was self-applied, sent by post accompanied with the informed consent. An extra envelope was added for the patients to send the signed informed consent and the questionnaire to the Hospital without cost. The questionnaire is showed on Table 11 . A positive result on the questionnaire was defined as an affirmative answer (''yes'') to questions 1 or 7 or any 3 other questions [18] . An extra 2 questions were added for data gathering purposes: "11 -Do you undertake testosterone replacement therapy at the moment?" and "12 -What is your height?". From the 45 males, 6 were deceased, so the questionnaire was sent to 39 males. From those 39, 2 didn't have a valid address or contact number and 3 didn't answer from health conditions such as cerebral stroke and mental incapability. A total of 34 valid questionnaires were received.
The study protocol was approved by the Hospital Ethical Committee and all patients provided written informed consent.
Statistical methods
Descriptive characteristics of the study population were tabulated as mean (SD) or median (minimum and maximum) according to the variables distribution, or proportions, as applicable. Student's t-test or MannWhitney U test were computed to compare the distributions of continuous variables between two independent samples. Differences of proportions among groups of patients were calculated with chisquare test or Fisher test as appropriate. The significance level was set at 5%.
Results
Of the 109 patients, 62 (33 males and 29 females) underwent one or more surgeries, with or without radiotherapy, but 3 (1 male and 2 females) lacked follow-up data, one of which due to the patient's death. The mean age at diagnosis was 51.8 years ± 17.26 (ranging from 18 to 91). The population of NFPA was formed by 64 (59%) females and 45 (41%) males. Most tumors were macroadenomas, 73 (67%) vs 36 (33%) microadenomas (p=0.001). Of the males, 40 (88%) had macroadenomas and 5 (12%) had microadenomas (p<0.001). Of the females, 33 (52%) had macroadenomas and 31 (48%) had microadenomas. Of the patients with macroadenomas 40 (55%) were males and 33 (45%) were females, but there is a different proportion of macroadenomas on males and females (88% vs 55%) (p<0.001). The median age of patients with microadenoma was 39 years (18-84), and the median age for macroadenomas was 59 years (24-91) (p<0.001). Only a minority was incidentally diagnosed, a total of 21 (19%) (p<0.001), of the females 12 (20%) and of the males 8 (18%). The median age of patients incidentally discovered was 58 years , and the median age for patients diagnosed when investigating symptoms related to the pituitary adenoma was 49 years . Of the incidentalomas, 11 (52%) were macroadenomas and 10 (48%) were microadenomas. Of the patients diagnosed when investigating symptoms (88 patients, 81%), 62 (70%) were macroadenomas and 26 (30%) were microadenomas.
Hormonal analysis:
On the pre-intervention evaluation, of the 109 patients, 66 (60%) were normal and 43 (40%) were HH. Of the 45 males, 18 (40%) were normal and 27 (60%) had HH. Of the 64 females, 48 (75%) were normal and 16 (25%) had HH. From the female normal group 32 (66%) were pre-menopause and 16 (33%) were post-menopause. Males underwent more surgery than females (60 vs 25%) (p<0.001). Of the macroadenomas, 39 (47%) had HH and 34 (53%) didn't, and of the microadenomas, 4 (11%) had HH and 32 (89%) didn't (p<0.001). Of the non-incidentalomas, 39 (44%) were HH and 49 (56%) weren't, and of the incidentalomas, 4 (19%) were HH and 17 (81%) weren't (p=0.03). There was a positive response to the GnRH test in 17 of the 30 patients (57%). Of the males 10 (47%) responded and of the females 7 (78%). There was difference between male and female age at diagnosis (58.1 vs 47.4) (p=0.001). Males were significantly older, more hypogonadal, more surgically or radiotherapy treated. All patients submitted to radiotherapy had previously undergone surgery. Median of age of patients that were submitted to surgery was 56 years (24-82) and median age for patients that didn't have surgery was 45.5 years . Of the males, 32 (71%) had surgery, 9 (50%) from the normal group and 23 (85%) from the HH group. Of the females, 27 (42%) had surgery, 16 (33%) from the normal group and 11 (69%) from the HH group. From the normal group 9 (56%) were pre-menopause and 7 (44%) were postmenopause. There was a difference between the number of males that underwent surgery and the females (71% of males, 42% of females) (p=0.03). Which translates that of the 59 patients that had surgery 32 (54%) were males and 27 (46%) were females. There was a positive response to the GnRH test after surgery in 9 of the 17 patients (53%). Of the males 5 (55%) responded and of the females 4 (50%) (table 5). Some of the patients had to be re-intervened after the first surgery. There were statistically significant differences between the groups with different number of surgeries. The outcome of these patients is shown on table 6. There was no statistically significant difference of outcome with age, gender, menopause or radiotherapy. The variation of the BMI before and after surgery according to their PGS is show on table 7. After surgery, patients with hypogonadism had a higher BMI than normal patients, but these results weren't statistically significant (table 7) . Their evolution with outcome is shown on table 8. Of the 34 valid questionnaires received, 28 (82%) had had surgery and 18 (53%) had HH. After the analysis of the questionnaires, 26 (76%) had symptoms of ED and 14 (21%) reported doing TRT. The median age of the population was 62 years (range 23-88). The median age of the males with ED was 65 and of the males without ED was 49, this difference was statistically significant. BMI of the groups is shown on table 9 and the median age on figure 1.
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Discussion
The population had a slight female predominance, 59% vs 41% males, which is coincident with previous studies [14] . The mean age at diagnosis was 51.8 years, supporting the previous data of the NFPA being frequent on the elderly. In this sample most patients were over 40 years old (71%) [7, 19] . Females were younger than males (table 1) . Most tumors were macroadenomas (67%, p=0.001) and proportionally males had more macroadenomas than females (88% vs 55%) (p<0.001). In Drange's, 77% of NFPA had macroadenomas and males had more frequently macroadenomas than females (92% vs 68%), and even though all these compared prevalences are higher than in our study, the tendency is similar to ours [14] . Patients with macroadenomas were older than patients with microadenomas (median 39 vs 59) (p<0.001).
Patients diagnosed incidentally are much less common (19%, p<0.001) and seem to be older (58 vs 49 years), but this wasn't statistically significant. Of the non-incidentalomas, most of them were macroadenomas (70%), just like in the whole population, and, proportionally, there is a higher number of microadenomas on the incidentally discovered group than the whole population (48% vs 33%), but this isn't statistically significant. Patients that had surgery seem to be older (median 56 vs 45.5 years), but this tendency is not statistically significant. Our sample has a similar number of patients intervened to other studies: 54% had surgery and 6% had radiotherapy [20] . There is a statistical difference between males and females on this distribution (71% of the males vs 42% of the females had surgery, respectively), which could be attributed to a highest rate of incidentally discovered NFPA on females, that are frequently less severe and less likely to have surgery. Most patients that had surgery were macroadenomas (97%, p<0.001) and most macroadenomas had surgery (78%, p=0.001). Of the patients that didn't have surgery, most of them were microadenomas (68%, p<0.001) and only a minority of microadenomas had surgery (10%, p=0.001). Of the incidentalomas only a minority had surgery (19%, p<0.001) and of the patients that didn't have surgery, 34% were incidentalomas vs 7% on the group that had surgery. But this difference wasn't statistically significant.. The prevalence of HH on our population was 40%, which is within the range found on previous studies (26% -72.6%) [7, [19] [20] [21] . The prevalence of HH was higher on males than females, both before and after surgery, 60 vs 25% and 62 vs 44%, respectively, but only the difference before surgery was statistically significant. There was no statistically significant improvement with surgery (only 17%) and some even became HH having previous normal PGS (13%), which is in agreement with other studies [19] [20] [21] .
Comparing males with females, 19% of the males improved vs 15% of females; 9% of the males worsened vs 18% of the females. Therefore, of the patients that improved, 40% were females vs 60% males and of those who worsened 62% were females vs 38% males. There seems to be a tendency for female patients to be more likely to worsen and less likely to improve than males (results not statistically significant). HH was less frequent on microadenomas (11% had HH and 89% didn't) (p<0.001). Patients incidentally diagnosed most frequently had normal PGS (81%, p=0.003). After surgery, there was a slight increase in HH on macroadenomas (47% before surgery vs 60% after surgery). Both microadenomas operated remained normal PGS and there was no difference of outcome on macroadenomas comparing with the whole population operated. When comparing with other pituitary adenomas populations, there are other causes for HH besides those of NFPA, such as direct hormonal interaction. On acromegaly, the mean age at diagnosis is 41-45 years, which is lower than that of NFPA, most patients had macroadenomas (77-86%), which was higher than in our series of NFPA (67%), but we had different proportion of macroadenomas in males vs females (88 vs 52%), unlike acromegaly, in which patients had a similar macroadenoma distribution according to gender [14, [22] [23] [24] . The prevalence of HH before intervention (surgery, radiotherapy or pharmacological treatment) is 53%, 46-53% on males and 46-60% on females, which is similar to that of NFPA [22, 23, 25] . The outcome varies significantly with the series and treatment approach, iatrogenic HH as low as 4.9% and as high as 41% [24, [26] [27] [28] . Prolactinomas are more frequent on females, as seen on NFPA, and the mean age at diagnosis is lower on females than males (32.7 vs 41.6), which is still lower than the mean age at diagnosis made on NFPA [14, 29] . The treatment of prolactinomas is in most cases pharmacological, but some patients are subjected to surgery. On Maric's study, 45% of the patients with prolactinomas had HH and with surgical approach there was a 20% improvement. In this study, most patients had microadenomas, only 36% were macroadenomas, which is the opposite proportion that we observe in NFPA, but on other study the prevalence of macroadenomas on prolactinomas can go up to 50%, which is still not the majority, as seen on NFPA [14, 29] . Like in our series of NFPA, on prolactinomas males seem to have more frequently macroadenomas than females (74% vs 40%) [14] . Even though there was a high rate of positive responses to the GnRH test (57% before surgery and 53% after surgery), besides lacking data on a high number of patients (and different missing data numbers on males vs females), no important information could be attained from these results. Even though this information would suggest that the HH on these patients was from hypothalamic and not pituitary causes on approximately half the sample, this test is neither sensitive nor specific for HH and positive response doesn't exclude nor ascertains pituitary or hypothalamic pathology, due to highly variable responses to GnRH stimulation [30, 31] . Therefore the clinical importance of this test to HH diagnosis seems to be obsolete, as it was reported previously [32] . Reoperation was done once on 10% of patients and twice on 5%, which is a slightly lower number than other studies (19% had 2 surgeries and 9% had 3 surgeries) [20] . Even though there was a statistically significant difference of outcome between the groups of different number of interventions, there isn't a tendency of increasing number of surgeries associated with worst prognosis, such information would only be supported comparing the group with 1 surgery and 3 surgeries. The increasing number of surgeries should be associated with increasing risk of iatrogenic HH. Nonetheless, the indication for surgery is often insufficient tumor removal on previous surgery or regrowth than presence of HH, which can cause different characteristics on the patients that undergo different number of surgeries, such as bigger tumors or more symptoms, information that is not accounted in this study and that associated with a small sample of patients, results in an impossibility to find that predictable causality of the iatrogenic effect.
Other factors didn't interfere in a statistically significant way on the outcome (such as age, gender or menopause).
There was a tendency of higher BMI for patients with HH than with normal PGS in all groups (before and after surgery). There was a tendency of increasing BMI from best to worst outcome: 27.1<27.6<30.0 for the improved (regained normal pituitary function), maintained previous pituitary function (either normal or HH) and worsened (became HH after surgery) groups, respectively. Despite these tendencies, these findings weren't statistically significant.
Most of the patients that answered the questionnaire had had surgery (82%) and about half had hypogonadism (53%). Patients that didn't have surgery had less HH (83%), which can arise from the fact that they probably had less severe symptoms or smaller tumors, that interfere less with adjacent structures (which reduces the probably of HH on NFPA patients), and don't have indication for surgery at the moment. This makes it expected that patients that had surgery had more HH (94%), more ED (85%) and were more frequently under TRT (93%) than those who didn't have surgery.
On the questionnaires analysis, we observed a tendency for patients that didn't undergo surgery or patients without HH being younger (51 vs 62.5 years and 56 vs 62.5 years, respectively). The presence of ED also followed this tendency and the difference in the median age was statistically significant between patients with and without ED (65 vs 49 years, respectively). There was a high prevalence of ED on our sample (76%), superior to the prevalence of HH (53%). Even though hypogonadism is a cause of ED, this difference on prevalences is most likely due to the high prevalence of older patients on the males subjected to the questionnaire (median 62 years) which is a known major risk factor for ED [33] . Therefore 46% of the patients with ED didn't have HH, being the ED from other causes. Only 55% of the patients with HH were under TRT, even if TRT replaces testosterone that should be produced on the end of the gonadal axis, which is damaged on HH. Also, patients under TRT were younger than those without TRT, even though younger patients have less HH and ED. Both these results can be justified by the fact that older patients have more contraindications for TRT (such as prostate pathology, severe cardiovascular diseases) or less potential benefits from improving from ED due to advanced age, which can explain this apparent contradiction of highest prevalence of disease (HH and ED) corresponding to lower use of treatment (TRT).
As we said before, HH can lead to weight gain and therefore obesity, but obesity is also a known factor for HH, so the causality relation between the two variables is unclear and may be a confunding factor [34] [35] [36] . There was no statistically significant difference among the groups regarding BMI, even though patients that underwent surgery seem to have higher BMIs comparing with those who didn't (28.0 vs 25.9). Studies mention a consistent decrease in total body fat associated with TRT on HH males, but this fact was not observed on our sample [36] . Since our analysis of BMI and TRT is transversal and the duration of treatment was not recorded, this may be an important fact to cause dispersion of any tendency to lower BMI on patients with HH taking TRT. Simultaneously, the presence of ED on patients under TRT translates inefficient treatment (79% of patients under TRT still have ED). This, associated with the fact that even though TRT could reduce BMI, doesn't improve cholesterol profile or have cardiovascular benefits, it makes us ponder the benefits of this treatment in comparison with its risks, especially since new studies suggest increased cardiovascular risk and all causes mortality on older patients, and on younger patients with pre-existing diagnosed heart disease, that do TRT [37] [38] [39] [40] .
Study limitations
The small number of patients on our sample damaged our statistical power to show some statistically significant results.
There are many confounding factors on the analysis of these results, since there is direct interference of the variables with one another, leading to blur on the tendencies and no statistical differences between the groups. For instance, patients with HH were treated with TRT, among other effects, to reduce ED, therefore the real prevalence of ED on patients with HH is underestimated.
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